Silent myocardial infarction

Summary

Silent myocardial infarction (MONDO:0003678) is a disease and 1 clinical trial. A subtype of myocardial infarction — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	silent myocardial infarction
Mondo ID	MONDO:0003678
DOID	DOID:5854
NCIT	C35400
SNOMED CT	233843008
UMLS	C0340324
MedGen	83307
Is cancer (heuristic)	no

Also known as: silent myocardial infarction

Disease family

This is a subtype of myocardial infarction. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › myocardial disorder › myocardial infarction › silent myocardial infarction

Related subtypes (13): posteroinferior myocardial infarction, septal myocardial infarction, posterior myocardial infarction, apical myocardial infarction, subendocardial myocardial infarction, posterolateral myocardial infarction, inferolateral myocardial infarct, lateral myocardial infarction, anteroseptal myocardial infarction, acute myocardial infarction, myocardial stunning, anterolateral myocardial infarction, inferior myocardial infarction

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01918150	PHASE4	UNKNOWN	Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII